GSK plc American Depositary Shares (Each representing two Ordinary Shares) (NY:GSK)

46.59 -0.45 (-0.95%)

Delayed Quote Updated: 1:50 PM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about GSK plc American Depositary Shares (Each representing two Ordinary Shares)

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

45 46 Next >

Wave Life Sciences Reveals RNA Editing Breakthrough, Reports First-Ever Clinical Proof-Of-Mechanism In Humans ↗

October 16, 2024

Wave Life Sciences' WVE-006 demonstrates first-ever RNA editing in humans for alpha-1 antitrypsin deficiency, showing favorable safety and efficacy in early trial results. GSK holds global license...

Via Benzinga

GSK Sues Moderna Alleging mRNA Vaccine Patent Infringement ↗

October 15, 2024

GlaxoSmithKline has filed a lawsuit against Moderna, claiming its mRNA vaccines infringe on GSK's patents. GSK seeks royalties for Moderna's alleged unlicensed use of its groundbreaking vaccine...

Via Benzinga

Topics Intellectual Property Lawsuit

GSK Says Depemokimab For Chronic Rhinosinusitis Reduces Nasal Polyp Size, Nasal Obstruction Versus Placebo At One Year ↗

October 14, 2024

GSK's depemokimab met key endpoints in phase 3 trials for chronic rhinosinusitis with nasal polyps (CRSwNP), showing promise in reducing nasal polyp growth and obstruction. Full results to be presented...

Via Benzinga

2 Best Artificial Intelligence Stocks to Buy in October ↗

October 13, 2024

These companies could have more growth ahead than investors realize.

Via The Motley Fool

Topics Artificial Intelligence

GSK Settles Majority Of Zantac Lawsuits, But Pipeline Doubts Remain ↗

October 11, 2024

GSK settles 93% of Zantac lawsuits with a $2.2 billion payout, easing investor concerns. However, doubts over its future growth persist as challenges with its drug pipeline remain.

Via Benzinga

Topics Lawsuit

World's Third-Largest OTC Player Sanofi's Consumer Health Unit Nears $16B Deal With Clayton Dubilier & Rice ↗

October 11, 2024

Sanofi is negotiating a potential sale of a 50% stake in its consumer health unit, Opella, to Clayton Dubilier & Rice. The deal, valued at $16.4 billion, could help Sanofi sharpen its focus on...

Via Benzinga

GSK, Pfizer Face Declining Respiratory Syncytial Virus Vaccine Sales Due To Narrow Age Recommendations ↗

October 10, 2024

RSV vaccine sales from GSK and Pfizer have dropped significantly following revised CDC guidelines, narrowing the eligible age group and reducing demand by two-thirds compared to last year.

Via Benzinga

Jim Cramer Likes Reddit Very Much, Calls Accenture A 'Great Buy' ↗

October 10, 2024

On CNBC's "Mad Money Lightning Round," Jim Cramer recommended buying Reddit, which went public earlier this year.

Via Benzinga

Why GSK Stock Rocketed Nearly 6% Skyward on Wednesday ↗

October 09, 2024

In a swarm of lawsuits, the company stood accused of selling a potentially cancer-causing medication.

Via The Motley Fool

Topics Lawsuit

Biden Administration Unveils Plan To Provide Generic Drugs for $2 to Medicare Recipients ↗

October 09, 2024

The Biden administration's proposed Medicare $2 Drug List Model aims to provide low-cost generic drugs for seniors and people with disabilities, with copayments capped at $2 per month for essential...

Via Benzinga

GSK Resolves Majority Of US Zantac Cases With $2.2B Settlement Deal, Stock Surges ↗

October 09, 2024

GSK has agreed to a $2.2 billion settlement to resolve the majority of U.S. state court Zantac lawsuits, with an additional $70 million set aside for a qui tam case. The company maintains there is no...

Via Benzinga

Topics Lawsuit

Merck's Mumps Vaccine Controversy: Class-Action Lawsuit Alleges Anticompetitive Behavior, Court Shields From Liability ↗

October 08, 2024

Merck faces a class-action lawsuit over alleged misrepresentation of its mumps vaccine potency, claiming anticompetitive practices to maintain market dominance. Despite ethical concerns, the court...

Via Benzinga

Topics Lawsuit

GSK Presents Positive Data for AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Indicating Protection Over Three RSV Seasons

October 08, 2024

From GSK plc

Via Business Wire

Pfizer Wins London Court Battle, GSK's Respiratory Syncytial Virus Vaccine Patents Invalidated ↗

October 07, 2024

Pfizer sees stock gains following a $1 billion investment by Starboard Value and a favorable UK court ruling invalidating two GSK RSV vaccine patents. Pfizer and GSK continue their legal battles as...

Via Benzinga

Topics Intellectual Property

Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks Delivering High-Dividend Yields ↗

October 07, 2024

Via Benzinga

GSK, Sanofi, And CSL Secure US Government Fund To Boost Bird Flu Vaccine Production: Report ↗

October 04, 2024

The U.S. government collaborates with GSK, Sanofi, and CSL to enhance bird flu vaccine production. This initiative aims to increase vaccine readiness to 10 million doses by early 2025 amid rising H5...

Via Benzinga

Medicare Drug Price Negotiation Program Gets Final Guidance For Second Cycle, $1.5B Savings Expected ↗

October 03, 2024

Guidance for the second cycle of Medicare drug price negotiations has expectations high for significant savings by 2026.

Via Benzinga

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More

October 03, 2024

Via Investor Brand Network

Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer’s and More

October 03, 2024

EQNX::TICKER_START (NYSE:ANVS),(NYSE:JNJ),(NYSE:NVS),(NYSE:MRK),(NYSE:GSK) EQNX::TICKER_END

Via FinancialNewsMedia

Pfizer Divests $3.3B Stake In Sensodyne Toothpaste And Panadol Painkiller Maker Haleon ↗

October 01, 2024

Pfizer has divested a $3.3 billion stake in Haleon, reducing its holding in the British consumer healthcare company.

Via Benzinga

Private Equity Firms Circle Sanofi's Consumer Health Business Amid Potential Spinoff ↗

September 25, 2024

Sanofi plans to spin off its consumer healthcare division, which could be valued at over $16.8 billion. Private equity firms are bidding for the unit, with the spinoff expected by Q4 2024. Banks...

Via Benzinga

Analysts Predict 85% Upside for Wave Life Sciences After Rate Cut

September 20, 2024

Wave Life Sciences has received recent Wall Street price targets forecasting big upside. The company has a potentially "industry-leading" treatment.

Via MarketBeat

Topics Economy

Alector Presents Baseline Characteristics for Pivotal INFRONT-3 Phase 3 Clinical Trial at the 14th International Conference on Frontotemporal Dementias (ISFTD 2024)

September 19, 2024

From Alector, Inc.

Via GlobeNewswire

AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation ↗

September 18, 2024

The FDA has approved AstraZeneca's Fasenra for eosinophilic granulomatosis with polyangiitis based on Phase 3 MANDARA trial results. The drug showed similar remission rates to GSK's Nucala.

Via Benzinga

GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults ↗

September 18, 2024

GSK released data from a Phase 3 trial evaluating the co-administration of Arexvy and Shingrix vaccines in adults 50+. The study showed a non-inferior immune response and good safety profiles. The...

Via Benzinga

GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX

September 18, 2024

From GSK plc

Via Business Wire

Nuvalent Flies On 'Multibillion-Dollar' Potential, While Iteos Crashes On Patient Deaths ↗

September 16, 2024

Nuvalent and Iteos delivered promising updates in their lung cancer studies. But three patients died in one test.

Via Investor's Business Daily

Topics Death

Moderna's Pain Continues Amid Flurry Of Downgrades Following 'Tough' R&D Day ↗

September 13, 2024

The company offered a series of updates that shook shares on Thursday. The selloff continued on Friday.

Via Investor's Business Daily

GSK Reveals 'Positive' Data From Mid-Stage Study Of Seasonal Influenza mRNA Vaccine ↗

September 12, 2024

GSK announced positive phase 2 trial results for its mRNA seasonal flu vaccine, showing strong immune.

Via Benzinga

GSK Halts Herpes Simplex Virus Vaccine Development, Clears Path For Other Contenders Like Moderna, BioNTech ↗

September 11, 2024

GSK Plc has halted development of its herpes simplex virus vaccine, GSK3943104, after it failed to meet efficacy goals in clinical trials. Moderna and Pfizer's partner BioNTech are still developing HSV...

Via Benzinga

< Previous 1 2

...

8 9 10 11 12 13 14 15 16

...

45 46 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.